In short
Clinical trials investigating Albiglutide are studying adults with type 2 diabetes. These trials look at how Albiglutide compares with other diabetes treatments and measure blood sugar control, especially HbA1c. The goal is to learn more about its effectiveness in people who need treatment for type 2 diabetes.
Key points
- Clinical trial data for Albiglutide focus on adults with type 2 diabetes. The listed study is a Phase 3 interventional trial with 781 planned participants. Researchers are measuring change in HbA1c, a key blood test for long-term blood sugar control. The study status is Authorised. Overall, the trial information shows Albiglutide being studied in a diabetes population with a focus on treatment effect over time.
Trial overview
The clinical trial listed for Albiglutide is NCT05433584, an interventional study in adults with type 2 diabetes. It is shown as Phase 3 and has a status of Authorised. The planned enrollment is 781 participants.
Who is being studied
This study is focused on adult participants with type 2 diabetes. The trial data do not list the full eligibility rules, so the exact entry criteria are not available here.
Study phase and design
The study is a Phase 3 trial, which usually means a larger study that compares treatment options and checks how well they work in real patient groups. It is also described as an interventional study, meaning researchers are testing treatments and measuring the results.
What is being measured
The main outcome is the change from baseline in hemoglobin A1c (HbA1c). HbA1c is a blood test that shows average blood sugar over time, so it helps researchers see whether treatment improves diabetes control. The study brief says the goal is to show that tirzepatide is non-inferior to intensified conventional care in HbA1c change from baseline to Week 104 in participants with type 2 diabetes.
Treatments in the study
The intervention list includes Albiglutide at 50 mg by injection, along with several other diabetes medicines and treatment options used for comparison in the study. These include sitagliptin, linagliptin, tirzepatide, semaglutide, exenatide, dulaglutide, liraglutide, lixisenatide, saxagliptin, pioglitazone, metformin, vildagliptin, and alogliptin, as well as some unnamed comparator entries in the trial record.
What the trial aims to show
The trial record is centered on comparing treatment effects in type 2 diabetes, with HbA1c as the key measure of success. For patients, this means the study is trying to learn whether the treatment strategy being tested can control blood sugar well over a long period, up to Week 104.